Abstract
An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry*
-
Cell Survival / drug effects
-
Cell Survival / physiology
-
Cyclooxygenase Inhibitors / administration & dosage
-
Cyclooxygenase Inhibitors / chemistry
-
Dose-Response Relationship, Drug
-
Drug Delivery Systems / methods*
-
HCT116 Cells
-
HeLa Cells
-
Hep G2 Cells
-
Histone Deacetylases* / administration & dosage
-
Humans
-
Indomethacin / administration & dosage
-
Indomethacin / chemistry*
-
Peptide Hydrolases* / administration & dosage
-
Prodrugs / administration & dosage
-
Prodrugs / chemistry*
Substances
-
Antineoplastic Agents
-
Cyclooxygenase Inhibitors
-
Prodrugs
-
Peptide Hydrolases
-
Histone Deacetylases
-
Indomethacin